Feasibility and Efficacy of Attentional-Control Training in Sickle Cell Disease
NCT05099874
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Children with sickle cell disease (SCD) exhibit significantly reduced cognitive functioning (often difficulties with attention) compared to peers and siblings without SCD. EndeavorRx (Akili Interactive Labs: Boston, MA) is an FDA-approved home-based, electronic attentional-control training program designed to treat attention problems in youth. Users access EndeavorRx on a tablet device for 25-30 minutes each day, 5 days per week, for 4 weeks.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Sickle Cell Disease
- Attention Deficit
- Cognitive Deficit in Attention
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 8 to 16 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Children's National Research Institute
- Last updated on ClinicalTrials.gov
- January 10, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
District of Columbia · 1
- Children's National Hospital · Washington D.C., DC
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.